



News & Information

Pompey, France, November 30, 2011

Novasep, a leading supplier of manufacturing solutions to the life sciences industry, is pleased to announce it has reached an agreement with the holders of a majority of its Notes, its Financial Shareholders and the *Fonds Stratégique d'Investissement* ("FSI"), the French Strategic Investment Fund, as a new investor.

The Restructuring Agreement setting out the principles governing the restructuring, including the steps which shall be followed in order to implement the restructuring, is expected to be signed by all parties early December 2011.

The company's outstanding notes will be reduced from c.€415m (including accrued interests) to €150m and its cash interests from approximately €40m to €12m per annum, thus significantly increasing Novasep's financial flexibility to take advantage of future growth opportunities.

Roger Marc Nicoud, Founder and CEO of Novasep commented: "*This consensual agreement is an outstanding outcome for Novasep, our employees, and all of our business partners. We believe the proposed de-levering of our balance-sheet will help create long term value, and we truly appreciate the strong support from our international investors, our current shareholders and the FSI. The Novasep management team looks forward to driving the company's growth strategy and continuing to develop our core markets*".

About Novasep: www.novasep.com

Novasep is a leading worldwide provider of integrated manufacturing solutions for Life Science industries. Novasep develops, markets and operates innovative technologies from lab to industrial scale to produce biomolecules and synthetic molecules for the pharmaceutical, biopharmaceutical, agrochemical, fine chemical and industrial biotechnology markets. Headquartered in Pompey, France, Novasep has six FDA-inspected manufacturing plants in France, Germany and the Bahamas, two biopharmaceutical production sites in Belgium, R&D and equipment manufacturing facilities in the USA, China and France, and an office in Japan. Novasep operates through two business lines: Novasep Synthesis, which uses a large range of chemical synthesis and purification technologies to develop and produce high value-adding active ingredients and advanced intermediates for the pharmaceutical, crop science and other fine chemical industries; and Novasep Process, which supplies innovative purification processes, equipment and systems for the pharmaceutical, biopharmaceutical and industrial biotechnology industries and provides contract manufacturing services for biopharmaceuticals.

Contacts

NewCap.

Investor Relations

Axelle Vuillermet / Emmanuel Huynh

Tel.: +33 (0)1 44 71 94 93

Email: novasep@newcap.fr